Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.38 | N/A | +55.74% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.38 | N/A | +55.74% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management expressed confidence in the company's position within the industry. However, they did not provide any forward-looking guidance.
Management highlighted strong performance in the genomic sequencing market.
They noted ongoing investments in research and development.
No specific guidance was provided for future quarters.
Illumina's earnings report showed a strong EPS beat, indicating better-than-expected profitability. However, the stock fell by nearly 4%, likely due to a lack of revenue details and forward guidance. Investors may be cautious given the absence of specific future expectations from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALBERTSONS CO SHS CL Class A